Covalon Technologies (CVE:COV) Sets New 1-Year High - Should You Buy?

Covalon Technologies Ltd. (CVE:COV - Get Free Report) shares hit a new 52-week high on Friday . The company traded as high as C$3.95 and last traded at C$3.82, with a volume of 11793 shares trading hands. The stock had previously closed at C$3.81.

Covalon Technologies Trading Up 6.3 %

The company has a quick ratio of 6.45, a current ratio of 5.24 and a debt-to-equity ratio of 4.98. The firm has a market capitalization of C$110.97 million, a P/E ratio of -101.25 and a beta of 0.64. The firm's 50-day simple moving average is C$3.32 and its 200-day simple moving average is C$2.51.

Covalon Technologies (CVE:COV - Get Free Report) last announced its earnings results on Wednesday, August 21st. The company reported C$0.06 earnings per share (EPS) for the quarter. Covalon Technologies had a negative net margin of 2.82% and a negative return on equity of 3.85%. The company had revenue of C$9.22 million during the quarter. Analysts anticipate that Covalon Technologies Ltd. will post 0.3 EPS for the current year.

Covalon Technologies Company Profile

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.